Hisham Ibrahim, MD
Nephrology · Winter Garden, FLNPI 1619918760
Payments from drug & device makers
What this record shows
This record is dominated by grants: $3,030 of the $3,471 with a category attached, or 87.3%. Abbott accounts for 89.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $3,046 and has fallen 96.3% since, to $114 in 2024.
Across 17 payments — averaging $204.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Otsuka America Pharmaceutical, Inc.$122
- OPKO Pharmaceuticals, LLC$68
- GSK$45
- Boston Scientific$33
- Alnylam Pharmaceuticals Inc.$28
- plus $64 from 4 others
What the payments were for
- Grants$3,03087%
- Food & beverage$34110%
- Education$1003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $3,112 |
| Otsuka America Pharmaceutical, Inc. | 3 | $122 |
| OPKO Pharmaceuticals, LLC | 3 | $68 |
| GSK | 2 | $45 |
| Boston Scientific | 1 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| AbbVie | 1 | $17 |
| Bayer | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| AstraZeneca | 1 | $15 |
How this compares
$3,471 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone | 22 | $6,929 |
| Valganciclovir Hcl | 31 | $6,010 |
| Cinacalcet Hcl | 24 | $2,077 |
| Nifedipine ErNifedipine | 50 | $1,048 |
| Prednisone | 207 | $964 |
| Hydralazine Hcl | 39 | $661 |
| Bumetanide | 19 | $521 |
| Carvedilol | 32 | $375 |
| Amlodipine Besylate | 55 | $347 |
| Atorvastatin Calcium | 36 | $303 |
| Tamsulosin Hcl | 25 | $298 |
| Pantoprazole Sodium | 22 | $246 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $179 |
| Metoprolol Succinate | 15 | $78 |
| Furosemide | 16 | $34 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Winter Garden
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
- Fouad ChebibJacksonville$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.